



This table summarizes COVID-19 vaccine eligibility based on patient age or health condition. The most current version of this table is available [online](#). **The mRNA COVID-19 vaccines are preferred over the Janssen/Johnson & Johnson COVID-19 vaccine for primary and booster vaccination.**

Vaccine	Dose	Age		
		5-11	12-17	18+
mRNA vaccines: Pfizer ¹ / Comirnaty & Moderna ²	Primary 2-dose series ³	Pfizer only ¹	Pfizer only	✓
	Third primary dose (“additional dose”) ^{3,4} recommended for moderate to severely immunocompromised persons at least 28 days after 2 nd dose	Pfizer only ¹	Pfizer only	✓
	Booster dose recommended ^{3,5} 5 months after a Moderna or Pfizer primary series		Pfizer only	✓
Janssen/ Johnson & Johnson (J&J)	<i>J&J vaccine is an alternate vaccine option for persons with contraindications to both mRNA vaccines or who prefer to get a J&J vaccine.</i>			
	Primary single-dose series ³			✓
	Booster dose recommended ^{3,5} (mRNA vaccine preferred) 2 months after the 1 st dose			✓
Fully Vaccinated with Alternative Series ⁶	Third primary dose (“additional dose”) ³ recommended for moderate to severely immunocompromised persons at least 28 days after 2 nd dose		Pfizer only	Pfizer only
	Booster dose recommended ³ 5 months after the 2 nd dose (after 3 rd dose if immunocompromised)		Pfizer only	Pfizer only

1. Pfizer has a different formulation for the 5-11 age group: 0.2 ml dose containing 10 µg in Tris buffer (orange cap).
2. Moderna has two dose volumes. The full dose (100 µg in 0.5 ml) is authorized for both the primary series and the 3rd dose for persons who are immunocompromised. A half dose (50 µg in 0.25 ml) is authorized for booster doses.
3. People with known current SARS-CoV-2 infection should defer vaccination until they have recovered from the acute illness (if symptoms were present) and they have discontinued isolation. For individuals diagnosed with MIS-C/MIS-A or for those who received passive antibody products, please refer to [Interim Clinical Considerations](#).
4. The third dose of mRNA vaccine should be the same vaccine product as the primary series, whenever possible.
5. Booster doses can be the same vaccine as was given in the primary series or can be a mix-and-match dose for people ages 18 and older. mRNA vaccines are recommended over J&J vaccine for boosters. Note: A Moderna booster dose is a half dose (50 µg in 0.25 ml). Only the Pfizer vaccine is authorized as a booster for persons ages 12 -17. Immunocompromised persons should receive a booster dose ≥ 5 months after their 3rd primary dose.
6. Persons who are considered [fully vaccinated](#) with a non-FDA authorized/approved series include those who completed a WHO-EUL COVID-19 vaccine series, those who completed a heterologous (mix and match) series composed of any combination of FDA-approved, FDA-authorized, or WHO-EUL COVID-19 vaccines, and those who have received the full series of an “active” (not placebo) COVID-19 vaccine candidate for which vaccine efficacy has been independently confirmed (e.g., by a data and safety monitoring board). Only the Pfizer COVID-19 vaccine is authorized as a booster or additional dose for people who did not receive an FDA authorized/approved COVID-19 vaccine series.

For more information, see CDC [Clinical Considerations for Use of COVID-19 Vaccines](#).